Role of the CCN protein family in cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Hyungjoo | - |
dc.contributor.author | Son, Seogho | - |
dc.contributor.author | Shin, Incheol | - |
dc.date.accessioned | 2021-08-02T12:53:53Z | - |
dc.date.available | 2021-08-02T12:53:53Z | - |
dc.date.created | 2021-05-12 | - |
dc.date.issued | 2018-10 | - |
dc.identifier.issn | 1976-6696 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/16027 | - |
dc.description.abstract | The CCN protein family is composed of six matricellular proteins, which serve regulatory roles rather than structural roles in the extracellular matrix. First identified as secreted proteins which are induced by oncogenes, the acronym CCN came from the names of the first three members: CYR61, CTGF, and NOV. All six members of the CCN family consist of four cysteine-rich modular domains. CCN proteins are known to regulate cell adhesion, proliferation, differentiation, and apoptosis. In addition, CCN proteins are associated with cardiovascular and skeletal development, injury repair, inflammation, and cancer. They function either through binding to integrin receptors or by regulating the expression and activity of growth factors and cytokines. Given their diverse roles related to the pathology of certain diseases such as fibrosis, arthritis, atherosclerosis, diabetic nephropathy, retinopathy, and cancer, there are many emerging studies targeting CCN protein signaling pathways in attempts to elucidate their potentials as therapeutic targets. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | KOREAN SOCIETY BIOCHEMISTRY & MOLECULAR BIOLOGY | - |
dc.title | Role of the CCN protein family in cancer | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Shin, Incheol | - |
dc.identifier.doi | 10.5483/BMBRep.2018.51.10.192 | - |
dc.identifier.scopusid | 2-s2.0-85055618802 | - |
dc.identifier.wosid | 000452146900003 | - |
dc.identifier.bibliographicCitation | BMB REPORTS, v.51, no.10, pp.486 - 492 | - |
dc.relation.isPartOf | BMB REPORTS | - |
dc.citation.title | BMB REPORTS | - |
dc.citation.volume | 51 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 486 | - |
dc.citation.endPage | 492 | - |
dc.type.rims | ART | - |
dc.type.docType | Review | - |
dc.identifier.kciid | ART002398111 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.relation.journalResearchArea | Biochemistry & Molecular Biology | - |
dc.relation.journalWebOfScienceCategory | Biochemistry & Molecular Biology | - |
dc.subject.keywordPlus | TISSUE-GROWTH-FACTOR | - |
dc.subject.keywordPlus | VASCULAR ENDOTHELIAL-CELLS | - |
dc.subject.keywordPlus | K-1735 MURINE MELANOMA | - |
dc.subject.keywordPlus | ARREST-SPECIFIC GENE | - |
dc.subject.keywordPlus | IMMEDIATE-EARLY GENE | - |
dc.subject.keywordPlus | DIFFERENTIAL EXPRESSION | - |
dc.subject.keywordPlus | FACTOR CTGF/CCN2 | - |
dc.subject.keywordPlus | HUMAN SKIN | - |
dc.subject.keywordPlus | INTEGRIN ALPHA(V)BETA(3) | - |
dc.subject.keywordPlus | POTENTIAL MECHANISM | - |
dc.subject.keywordAuthor | Cancer | - |
dc.subject.keywordAuthor | CCN family | - |
dc.subject.keywordAuthor | Matricellular protein | - |
dc.subject.keywordAuthor | Signal transduction | - |
dc.subject.keywordAuthor | Therapeutic target | - |
dc.identifier.url | https://www.bmbreports.org/journal/view.html?doi=10.5483/BMBRep.2018.51.10.192 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.